Human Molecular Genetics Program, Lurie Children's Research Center, Chicago, IL 60614, USA.
Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Biol Chem. 2018 Feb 23;399(3):219-234. doi: 10.1515/hsz-2017-0249.
Chronic respiratory diseases encompass a group of diverse conditions affecting the airways, which all impair lung function over time. They include cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and asthma, which together affect hundreds of millions of people worldwide. MicroRNAs (miRNAs), a class of small non-coding RNAs involved in post-transcriptional gene repression, are now recognized as major regulators in the development and progression of chronic lung disease. Alterations in miRNA abundance occur in lung tissue, inflammatory cells, and freely circulating in blood and are thought to function both as drivers and modifiers of disease. Their importance in lung pathology has prompted the development of miRNA-based therapies and biomarker tools. Here, we review the current literature on miRNA expression and function in chronic respiratory disease and highlight further research that is needed to propel miRNA treatments for lung disorders towards the clinic.
慢性呼吸系统疾病包括一组影响气道的不同疾病,这些疾病都会随着时间的推移而损害肺功能。它们包括囊性纤维化 (CF)、特发性肺纤维化 (IPF)、慢性阻塞性肺疾病 (COPD) 和哮喘,这些疾病共同影响着全球数以亿计的人。microRNAs (miRNAs),一类参与转录后基因抑制的小非编码 RNA,现在被认为是慢性肺部疾病发展和进展的主要调节因子。miRNA 丰度的改变发生在肺组织、炎症细胞中,并且可以在血液中自由循环,被认为既是疾病的驱动因素,也是疾病的修饰因子。它们在肺病理学中的重要性促使 miRNA 治疗和生物标志物工具的发展。在这里,我们回顾了 miRNA 在慢性呼吸系统疾病中的表达和功能的现有文献,并强调了进一步研究的必要性,以推动针对肺部疾病的 miRNA 治疗进入临床。